SCHEMBL1407121

SCHEMBL1407121

CCOC(=O)c1cnn([C@H]2CC[C@@H](O)CC2)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.44
JAK3 P52333 3/20 0.42
JAK1 P23458 2/20 0.42
ALDH1A1 P00352 6/20 0.41
NPSR1 Q6W5P4 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407122 1.00 LMNA (0.44) LMNAJAK3JAK1ALDH1A1NPSR1
SCHEMBL1407037 0.95 LMNA (0.47) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL1407209 0.90 LMNA (0.48) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL1406792 0.90 LMNA (0.51) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL1406968 0.88 LMNA (0.53) LMNAALDH1A1NPSR1KMT2AMEN1
SCHEMBL17097772 0.88 HSD11B1 (0.45) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL17098124 0.88 LMNA (0.45) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL17110181 0.88 LMNA (0.42) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL17097774 0.88 HSD11B1 (0.45) LMNAALDH1A1NPSR1KMT2ASMN1; SMN2
SCHEMBL1406858 0.86 PDE4B (0.48) LMNASMN1; SMN2GAAKDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999114-B1 PYRAZOLES AS 11-BETA-HSD-1 HOFFMANN LA ROCHE (CH) 2015-07-22 EP disclosed
EP-2295411-A1 Pyrazoles as 11-beta-hsd-1 F. Hoffmann-La Roche AG (CH) 2011-03-16 EP disclosed
US-7728029-B2 Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase HOFFMANN-LA ROCHE INC. (US) 2010-06-01 US disclosed
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase ANDERSON KEVIN WILLIAM 2007-09-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225280-A1 Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase HSD3B2, HSD3B1, HSD17B2 LMNA 2991/4885JAK3 3992/4885JAK1 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.